Lifecore Biomedical (NASDAQ: LFCR) announced a new commercial site‑transfer agreement that marks the company’s third such win in five months. The deal will bring a market‑approved sterile aesthetic product—currently manufactured in‑house outside the United States—into Lifecore’s U.S. facility. The company expects commercial revenue from the transfer to begin within 24 months, a contribution that supports its target 12% compound annual growth rate through 2029.
Under the agreement Lifecore will provide technical transfer services, including process performance qualification (PPQ) batches, to enable the customer’s production of the sterile product. The transfer will occupy an estimated 5% to 10% of the facility’s capacity once commercialized, and it represents the first entry into the medical‑aesthetics modality, a new therapeutic area for the company. The expansion aligns with Lifecore’s strategy of pursuing lower‑risk, late‑stage programs and site transfers that offer a faster path to revenue than traditional development projects.
Lifecore’s recent financial performance provides context for the deal. In fiscal 2024 Q4 the company reported revenue of $37.9 million and a net loss of $7.1 million, while fiscal 2025 Q1 revenue was $24.7 million with a net loss of $16.2 million. The company’s 2026 revenue guidance is $120–$125 million and adjusted EBITDA guidance is $20.5–$25 million. Lifecore also aims to raise capacity utilization from 20% to 60% by 2029, a target that the new agreement helps to advance.
CEO Paul Josephs said, “We are thrilled to announce the signing of our third commercial site transfer in a relatively short amount of time. We believe these high‑value wins reflect Lifecore’s robust quality standards, strong compliance track record, as well as our proven ability to professionally meet the significant demands of commercial production.” The agreement validates Lifecore’s focus on lower‑risk, late‑stage programs and expands its footprint into a high‑growth aesthetics market, positioning the company to accelerate revenue growth and improve margin performance as capacity utilization rises.
The site‑transfer win diversifies Lifecore’s customer base and adds a new revenue stream that is expected to contribute to the company’s long‑term growth targets. By leveraging its technical expertise and expanding into a new therapeutic area, Lifecore is strengthening its competitive position in the CDMO market and moving closer to achieving the 12% CAGR and EBITDA margin goals set for 2029.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.